000739:SHE
Apeloa Pharmaceutical Co Ltd
CN¥23,42
arrow_downward
-1,64%(-0,39) 1D
16 ຕ.ລ., 15 ໂມງ 4 ນາທີ 48 ວິນາທີ GMT+8 · CNY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 000739...
Open
CN¥24,04
High
CN¥24,76
Low
CN¥23,09
Mkt. cap
27,13 ຕື້
Avg. vol.
16,27 ລ້ານ
Volume
15,09 ລ້ານ
Dividend
1,61%
Quarterly dividend
CN¥0,09
Ex-dividend date
8 ຕ.ລ. 2026
P/E ratio
31,78
52-wk high
CN¥28,50
52-wk low
CN¥14,89
EPS
CN¥0,74
Shares outstanding
1,16 ຕື້
No. of employees
7 ພັນ
Open
CN¥24,04
High
CN¥24,76
Low
CN¥23,09
Mkt. cap
27,13 ຕື້
Avg. vol.
16,27 ລ້ານ
Volume
15,09 ລ້ານ
Dividend
1,61%
Quarterly dividend
CN¥0,09
Ex-dividend date
8 ຕ.ລ. 2026
P/E ratio
31,78
52-wk high
CN¥28,50
52-wk low
CN¥14,89
EPS
CN¥0,74
Shares outstanding
1,16 ຕື້
No. of employees
7 ພັນ
News stories
From web sources and news partners
GlobeNewswire
·
41 ນາທີກ່ອນ
OpenWorld (NASDAQ: OPNW) Signs Definitive Merger Agreement to Acquire Blocksight
Business Wire
·
1 ຊົ່ວໂມງກ່ອນ
Faraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: FFR to Hold Listing Ceremony and First Investor Day at the Nasdaq Tower on Oct. 26; Three New Robotics Product Offerings Launched
marketscreener.com
·
6 ນາທີກ່ອນ
CECO Environmental Corp. Primary Exchange Listing will Change to Texas Stock Exchange from Nasdaq Global Select
Bloomberg.com
·
2 ຊົ່ວໂມງກ່ອນ
US Stock Futures Rise Ahead of Busy Earnings Week: Markets Wrap
Profile
Apeloa Pharmaceutical Co., Ltd., known as Apeloa, is a Chinese pharmaceutical manufacturer under Hengdian Group. The company is headquartered in Hengdian, Dongyang, Zhejiang, China. It was founded in 1989 and has been listed on the Shenzhen Stock Exchange since 9 May 1997. Apeloa provides contract development and manufacturing services and manufactures APIs and finished dosage forms; products span cardiovascular, anti-infective, psychiatric and oncology areas.
Apeloa has 7400 employees, 8 manufacturing sites and 3 R&D centers in Boston, Shanghai and Hengdian, covering flow chemistry, synthetic biology and biocatalysis, and peptide development. It has invested over USD20 million in flow chemistry over the past ten years in an effort to advance sustainable pharmaceutical manufacturing. In Boston, its 17,000-square-foot facility does R&D related to chemistry needs in drug development, including preclinical chemistry, scale-up production and new drug development.
Apeloa Pharmaceutical has successfully passed 20 U.S. FDA inspections since 2006. Wikipedia
About Apeloa Pharmaceutical Co Ltd